A Preliminary Study on the Ability of a Trypsin Like Peptidase Activity Assay Kit in Detecting Periodontitis among patients visiting the College of Dental Medicine Rangsit University

开始日期2025-02-16

申办/合作机构

Rangsit University

TCTR20250317013

/ RecruitingN/AIIT

The relation between reflex and coordination in children with developmental coordination disorder

开始日期2025-01-03

申办/合作机构

Rangsit University

100 项与 Rangsit University 相关的临床结果

登录后查看更多信息

0 项与 Rangsit University 相关的专利（医药）

登录后查看更多信息

2,592

项与 Rangsit University 相关的文献（医药）

2025-12-01·Cancer Chemotherapy and Pharmacology

Influence of DPYD gene polymorphisms on 5-Fluorouracil toxicities in Thai colorectal cancer patients

Article

作者: Puangpetch, Apichaya ; Fabienne, Thomas ; Chamnanphon, Monpat ; Sankuntaw, Nipaporn ; Aiempradit, Somthawin ; Vanwong, Natchaya ; Atasilp, Chalirmporn ; Chansriwong, Phichai ; Jinda, Pimonpan ; Satapornpong, Patompong ; Reungwetwattana, Thanyanan ; Sirachainan, Ekaphop ; Sirilerttrakul, Suwannee ; Sukasem, Chonlaphat ; Yodwongjane, Pavitchaya

DPYD polymorphisms have been widely found to be related to 5-FU-induced toxicities. The aim of this study was to establish significant associations between five single-nucleotide polymorphisms of DPYD and 5-FU hematological toxicities in Thai colorectal cancer patients. The toxicities were analyzed at the first and second cycles of 5-FU administration in 75 patients. Genotyping was performed using TaqMan real-time PCR. The genotype frequencies of DPYD*2A,1905 + 1 G > A and DPYD 1774 C > T were all wild type. The frequencies of genetic testing for DPYD*5, 1627 A > G, DPYD 1896T > C, and DPYD*9A, 85 A > G were 37.30% (AG; 34.60%, GG; 2.70%), 32.00% (TC; 25.30%, CC; 6.70%), and 13.40% (AG; 10.70%, GG; 2.70%), respectively. The results reveal significant findings with neutropenia occurring in 100% (2/2) of the patients with homozygous variant DPYD*9A (GG) from the first cycle of treatment for both Grade 1-4 and Grade 3-4 toxicities (P = 0.003 and P < 0.001 respectively). DPYD *9A was related to Grade 1-4 leukopenia (P = 0.001) and both Grade 1-4 and severe thrombocytopenia (P < 0.001 and P < 0.001) in the first cycle. In the second cycle, DPYD*5 was shown to be closely associated with no Grade 1-4 toxicity (P = 0.02). However, we found that 100% (2/2) of patients carrying the homozygous variant (GG) DPYD*5, presented no significant toxicity, so, DPYD*5 may be a predictive marker of neutropenia in patients treated with 5-FU. These outcomes suggest that there may be an increased risk of developing 5-FU-induced neutropenia in patients carrying the DPYD*9A, which should be considered as part of the standard procedure.

2025-07-01·Epilepsy & Behavior

Response to nitrazepam in infantile epileptic spasms syndrome after failed standard treatment

Article

作者: Sri-Udomkajorn, Somjit ; Suwannachote, Sirorat ; Boonkrongsak, Rachata ; Wittawassamrankul, Raviwan ; Sakpichaisakul, Kullasate ; Areekul, Sunichaya

OBJECTIVEOver half of children with infantile epileptic spasms syndrome (IESS) do not respond to standard treatments. Nitrazepam has shown efficacy similar to adrenocorticotrophic hormone. This study evaluated response rates, adverse effects of nitrazepam, and factors associated with responders in children with IESS who failed standard treatment.METHODSWe conducted a retrospective observational study of children with IESS who failed standard treatments and subsequently received nitrazepam between January 1, 2013, and December 31, 2021. Responders were defined as those achieving sustained clinical resolution of epileptic spasms without relapse at the 3-month follow-up. Etiologies were classified according to the 2017 International League Against Epilepsy classification.RESULTSThe study included 85 children, with 26 (30.5 %) children showing a response to nitrazepam. Adverse effects occurred in 52 (61.2 %) children, with hypersalivation (47.1 %) being the most common. At the 12-month follow-up visit, 20 (23.5 %) children had sustained clinical resolution of epileptic spasms, with no recorded deaths. Etiology was known in 73.3 % (structural 52 %; infectious 10.7 %; genetic 8 %; metabolic 2.7 %) and unknown in 26.7 %. Known etiology increased the likelihood of responding to nitrazepam (adjusted OR 5.78, 95 % CI 1.17, 28.72, p = 0.032), while a longer duration from epileptic spasms onset to nitrazepam decreased the odds of response (adjusted OR 0.85, 95 % CI 0.74, 0.98, p = 0.021).CONCLUSIONApproximately, 31% of children responded to nitrazepam. Early initiation of treatment with nitrazepam may be beneficial for children with IESS, particularly those with a known etiology, after failure of standard treatments.

2025-07-01·Polymer Degradation and Stability

Novel one-pot recovery and in-situ crystallization of polyhydroxybutyrate and hydroxyapatite/tricalcium phosphate biocomposite microparticles with comparative life cycle assessment

作者: Worajittiphon, Patnarin ; Boonyagul, Sani ; Wongsirichot, Phavit ; Rachtanapun, Pornchai ; Thanakornkriengkrai, Thanadol ; Neerawong, Purin ; Tanadchangsaeng, Nuttapol ; Kuncharin, Pasin ; Panaksri, Anuchan ; Wangtueai, Sutee ; Jantanasakulwong, Kittisak ; Panthong, Taranuch ; Sathirapongsasuti, Nuankanya ; Pichaiaukrit, Woradej

Formation of polyhydroxybutyrate (PHB) biopolymer composites with bioceramics such as hydroxyapatite (HA) and tricalcium phosphate (TCP) is essential in achieving mech. properties needed for novel bone tissue engineering using PHB.However, composite microparticle synthesis typically requires multiple steps, including 1) PHB recovery and purification, 2) dispersion of HA and TCP particles in the melt or solvent-dissolved polymer liquid, and 3) micro-droplet drying.In this study, PHB/HA/TCP composite microparticles were successfully produced by one-pot biosynthesis.This was achieved during acid-based PHB recovery by utilizing the crystallization of native-amorphous granule PHB within Cupriavidus necator.In-situ PHB crystallization was successfully monitored by real-time attenuated total reflection-Fourier transform IR (ATR-FTIR).Addnl., the in-situ crystallization behavior was elucidated by SEM and transmission electron microscopy (TEM).The most suitable conditions for synthesis of the PHB/HA/TCP composite were pH 2, and 20 min of reaction time, which capitalizes on the amorphous nature of the in-situ PHB during recovery.The HA and TCP did not function as nucleating agents, thereby not impacting accumulation and homogeneity.This allows HA/TCP bioceramics to be inserted into the polymer during the PHB recovery period, and after the crystallization step is completed, the composite microparticles could facilely form.The crystallization mechanism was found to be sporadic, and the morphol. was a disk with two dimensions.Addnl., the life cycle assessment (LCA) revealed that the one-pot method reduced global warming potential (GWP) emissions by 50% and non-renewable energy use (NREU) by a comparable margin, compared to the conventional multi-step method for HA/TCP (20:80) productionThese findings emphasize the environmental advantages of the one-pot approach alongside its cost and process efficiency.The demonstrated one-pot synthesis method would allow for more streamlined and cost-effective production of PHB/HA/TCP biocomposites.The materials produced and insights gained will be beneficial for future development of biopolymer composite processing and biomedical applications.

100 项与 Rangsit University 相关的药物交易

登录后查看更多信息

100 项与 Rangsit University 相关的转化医学

登录后查看更多信息